Dr. Niro Anandasabapathy completed physician scientist training (M.D. Ph.D.) from Stanford with Garry Fathman, a leader in T cell immunity, and post-doctoral fellowship at the Rockefeller University with the renowned Dendritic cell biologist Ralph Steinman (2011 Nobel Prize in Medicine). During her post-doctoral studies, she developed advanced methodologies to distinguish the differentiation of DC from other myeloid cells and used this to demonstrate tonic Dendritic cell surveillance along peripheral tissue sites including the choroid plexus and meninges of the brain. Separately, she brought Fms-like tyrosine kinase 3 (Flt3L) back into clinical development, running the Phase I Flt3L trial in healthy volunteers, while obtaining her M.S. in Clinical Investigation (CTSA KL2), receiving a K23 award from the NIH, and demonstrating DC expansion and skewing by Flt3L could enhance CD4 and CD8 immunity and DC cross-presentation, the basis for current efforts with Flt3L in the tumor setting. In 2012 Niro established her independent laboratory at Brigham and Women's Hospital, Harvard Medical School, as a faculty member in Dermatology, Immunology, and as a member of the Harvard Stem Cell Institute. She received multiple prestigious career grants (Sanofi, Cancer Research Institute, Melanoma Research Foundation, Dermatology Foundation, NIH R01) and was senior author on several high impact publications investigating the role of Dendritic cells in tissues and in cancers arising from the tissue including melanoma.

            She moved to Weill Cornell in 2018 as Dermatology Vice Chair for Research, a member of the Englander Institute for Precision Medicine and Meyer Cancer Center. She serves as Institutional Associate Director of the Tri-Institutional Medical Scientists training program. Her foundational work, translational excellence and contributions to in the fields of tissue immunity, and tumor immunity are recognized with continuous NIH R01 awards, an NIH S10, and membership to the Parker Institute in Cancer Immunotherapy.